Kisspeptin

The row below carries a price per mg figure: listed price divided by stated peptide content, excluding shipping and codes. It is the same calculation applied on every compound page, so a figure here is directly comparable to one anywhere else on the site.

We currently track a single listing for this compound. When a second vendor is added the rows are ordered by measured $/mg, and the flags for testing and shipping are computed from the data shown. Each row carries its own verification date.

Kisspeptin-10 · KP-10 · Metastin (45-54) · KiSS-1 (45-54) · KISS1 (112-121)

The ten residues sum to 1465.57 Da as free amino acids. Removing nine waters for the nine peptide bonds gives 1303.39 Da, and converting the C-terminal carboxyl to a carboxamide gives 1302.40 — matching the reported value. Element counts resolve to C63H83N17O14.

Both positional names in circulation are correct; they use different reference frames, which is a common source of confusion.

KISS1 (112-121) positions within the 145-residue KISS1 gene product (the full precursor protein) Metastin (45-54) positions within kisspeptin-54, the 54-residue mature peptide cleaved from that precursor

Same ten residues, two coordinate systems. Seeing both on one page is not an inconsistency.

The KISS1 gene encodes a 145-residue precursor. Proteolytic processing yields a family of peptides of differing length that all terminate in the same ten residues.

Kisspeptin-54 also called metastin — the longest mature form Kisspeptin-14 Kisspeptin-13 Kisspeptin-10 the C-terminal decapeptide

Every member shares this identical C-terminal decapeptide, and kisspeptin-10 is the shortest fragment that retains binding and activation at the receptor. That is the reason KP-10 rather than KP-54 is the standard research tool: it is the minimal active unit.

The sequence ends Arg-Phe-NH2 — an arginine-phenylalanine-amide motif that places kisspeptin in the RFamide peptide family. The C-terminal amide is not decorative. Amidation is required for receptor activation, and the free-acid form is substantially less active. Any material supplied without the terminal amide is a different and largely inactive compound.

The two names attach to two entirely separate discoveries about the same gene, made in the opposite order from what the reproductive literature would suggest.

KISS1 was first identified as a metastasis-suppressor gene. Its product was named metastin for that reason, and the gene was labelled KiSS-1 — a nod to Hershey, Pennsylvania, where the work was carried out.

Only later was the receptor GPR54 linked to reproduction, when loss-of-function mutations were found to cause idiopathic hypogonadotropic hypogonadism, and gain-of-function mutations central precocious puberty. That finding established kisspeptin as the gatekeeper of the reproductive axis.

The compound therefore has two largely independent research literatures — oncology and cell motility on one side, neuroendocrine reproduction on the other — and the two use opposite framings. In reproduction it is a stimulator; in cancer models it is an inhibitor of migration and invasion. Both are well documented and neither contradicts the other, but conflating them produces nonsense.

KISS1R, also designated GPR54 — a Gq/11-coupled G protein-coupled receptor.

Receptor activation engages phospholipase C, generating inositol phosphates and mobilizing intracellular calcium, with downstream ERK1/2 phosphorylation. Inositol phosphate accumulation in KISS1R-expressing HEK293 cells is the standard functional readout.

Kisspeptin neurons sit immediately upstream of GnRH neurons, and this is the architectural point that matters:

→ GnRH release from the hypothalamus → LH and FSH from the anterior pituitary → gonadal steroidogenesis and gametogenesis

Because kisspeptin acts one step above GnRH, it drives the axis through the endogenous GnRH pulse generator rather than bypassing it. This is the functional distinction from a GnRH agonist, which acts directly at the pituitary and produces desensitization on continuous exposure.

Arcuate kisspeptin neurons co-express neurokinin B and dynorphin — the KNDy population — and this trio is implicated in generating the pulsatile pattern of GnRH release rather than merely permitting it.

The core literature. Kisspeptin/GPR54 signalling is required for pubertal onset and for maintenance of reproductive function.

Human mutations in either partner produce hypogonadotropic hypogonadism or precocious puberty depending on direction of effect.

Functional MRI work reports that kisspeptin administration modulates activity in brain regions associated with sexual and emotional processing, including hippocampus and cingulate cortex.

In women with hypoactive sexual desire disorder, kisspeptin infusion altered brain responses to erotic stimuli and facial attractiveness, with correlated reductions in sexual aversion.

In men with HSDD, a randomized clinical trial reported a 56% increase in penile tumescence alongside increased subjective arousal.

(Comninos et al., JCI, 2017; Thurston et al., JAMA Netw Open, 2022; Mills et al., JAMA Netw Open, 2023)

A less obvious application with concrete numbers. In vitro, reported increases in osteoblast alkaline phosphatase of 41% with a 53% reduction in osteoclast resorptive activity. In healthy men, kisspeptin infusion increased the bone-formation marker osteocalcin by 24%, independent of sex steroid levels — implying a direct action on bone rather than one mediated through the gonadal axis.

(Comninos et al., JCEM, 2022; Mills et al., 2024)

Kisspeptin can trigger oocyte maturation by inducing an endogenous LH surge, and has been examined as an alternative to hCG as an IVF trigger. Because the surge is physiological and self-limiting rather than sustained, reduced risk of ovarian hyperstimulation syndrome has been reported. Separate work reports KP-10 inhibiting OHSS through suppression of VEGF secretion.

(Abbara et al.; Zhai et al., 2017)

Kisspeptin neurons respond to metabolic cues and are described as the interface aligning reproductive function with energy availability. Receptors are reported in brain, pancreas and brown adipose tissue. Disrupted signalling appears in obesity, diabetes and undernutrition. Related work reports effects on glucose homeostasis and on beta-cell function.

(Navarro, 2020; Izzi-Engbeaya et al., 2019; Sliwowska et al., 2024)

The metastasis-suppressor line. In the HTR8SVneo placental line, KP-10 reduced cell migration via an ERK1/2-p90rsk-GSK3β-FAK feedback loop. In first-trimester trophoblast, KP-10 raised intracellular calcium and inhibited motility without affecting proliferation, with altered expression of matrix metalloproteinases, their tissue inhibitors, and VEGF-A.

(Roseweir et al., Placenta, 2012; Bilban et al., J Cell Sci, 2004; Francis et al., PLoS One, 2014)

In SH-SY5Y-derived neurons overexpressing wild-type or E46K mutant α-synuclein, KP-10 reduced α-synuclein-linked apoptosis and mitochondrial depolarization — and did so in a KISS1R-independent manner, which is notable as an off-target mechanism.

(Simon, Soga & Parhar, IJMS, 2023)

Reported changes in intracellular collagen content and focal adhesion kinase phosphorylation, with shifts in matrix metalloproteinase and tissue inhibitor release.

(Radwańska et al., Sci Rep, 2023)

A DOTA-conjugated kisspeptin-10 has been synthesized and shown to retain comparable KISS1R activation, evaluated as a candidate gallium-68 / lutetium-177 pan-tumour radiopharmaceutical.

(Kleynhans et al., J Neuroendocrinol, 2025)

Functional hypothalamic amenorrhea, polycystic ovary syndrome, endometriosis, prolactin interaction, thermoregulation via KNDy neurons, kisspeptin as a urinary or serum biomarker in early pregnancy and miscarriage prediction, and intranasal administration stimulating gonadotropin release.

Kisspeptin is not approved by the FDA for any human indication. Clinical work has reached randomized controlled trials in hypoactive sexual desire disorder and has been examined as an IVF trigger, but no approved product exists. Reported adverse effects in short controlled studies are described as mild and include headache, flushing and nausea.

Material supplied for laboratory use is a research chemical. It is not a drug, food, cosmetic, or dietary supplement, has not been evaluated by the FDA, and is not intended for human or veterinary use.